(AORT) Artivion, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AORT) Artivion, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Artivion, Inc. BCG Matrix helps you quickly see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation analysis. The content on this page is a real preview of the actual report, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
E-nside; CE-marked off-the-shelf TAAA device; complex aortic repair
E-nside is a CE-marked, off-the-shelf TAAA device for complex aortic repair, placing Artivion, Inc. in the fastest-growing niche of its portfolio. Thoraco-abdominal aortic repair is moving from open surgery toward endovascular, branch-based solutions, and ready-to-use inventory matters in urgent cases where delay can raise risk.
This supports faster adoption and stronger mix shift as hospitals look for minimally invasive options with immediate availability.
E-vita THORACIC 3G; thoracic aortic aneurysm repair; endovascular growth
E-vita THORACIC 3G sits in a Star niche because thoracic aortic repair is a specialty use case that keeps growing as hospitals shift from open surgery to endovascular care. Artivion’s focus on complex aortic disease helps defend share where clinical know-how and surgeon trust matter most. In a market where minimally invasive repair is taking more cases, this product can keep compounding with procedural volume.
E-tegra; abdominal aortic aneurysm system; minimally invasive trend
E-tegra fits a Star profile if Artivion keeps share in AAA repair, because endovascular aneurysm repair keeps taking cases from open surgery and specialists still want dedicated systems with broad anatomical reach. The segment is large and recurring, so even modest share gains can matter. In BCG terms, this is a growth plus share play, not a niche device bet.
E-vita Open Neo; next-generation open repair platform; arch surgery
E-vita Open Neo fits the Stars bucket because it serves advanced aortic arch repair, a small but high-value referral niche where complex cases stay concentrated in top centers. Its ongoing rollout and clinical use can support share gains, since arch surgery drives premium pricing and repeat adoption when outcomes are strong.
- High-acuity arch cases support premium demand
- Ongoing use can expand center adoption
- Referral concentration favors specialized platforms
Ascyrus Medical Dissection Stent; acute dissection therapy; specialist adoption
Ascyrus Medical Dissection Stent fits Artivion’s Stars quadrant: it targets acute aortic dissection, a high-acuity condition that still needs faster, cleaner repair options. Hybrid and endovascular aortic care is expanding, so specialty-center use can lift demand if Artivion keeps funding training and clinical data. Its real value is in niche adoption, where surgeon preference and center protocols can drive share gains.
- Targets acute aortic dissection.
- Best suited to specialty centers.
- Growth tied to hybrid adoption.
Artivion’s Aortic Stars Are Winning Share as Endovascular Care Expands
Artivion’s Stars are E-nside, E-vita THORACIC 3G, E-tegra, E-vita Open Neo, and Ascyrus Medical Dissection Stent: they sit in growing, specialist aortic niches where endovascular care is taking share from open surgery. These products can keep compounding because urgent, high-acuity cases reward fast access, surgeon trust, and referral-center adoption.
| Product | Star signal | Why it matters |
|---|---|---|
| E-nside | Complex TAAA growth | Ready-to-use urgent repair |
| E-vita THORACIC 3G | Thoracic shift | Endovascular adoption |
| E-tegra | AAA share | Broad aneurysm reach |
What is included in the product
Detailed Word Document
Artivion’s BCG Matrix maps its product lines to show where to invest, hold, or divest amid growth and competitive pressures.
Editable Excel File
Quick BCG view of Artivion, Inc. helps spot pain points and prioritize products fast for clearer strategy.
Reference Sources
Provides a clear source trail for Artivion, Inc., helping decision-makers verify claims fast and trust the analysis.
Cash Cows
BioGlue; surgical sealant; long-established brand
BioGlue is a mature cash cow for Artivion, with strong brand recall and use across four surgery areas: cardiac, vascular, neurological, and pulmonary. Its long market life supports steady repeat demand, which is the kind of profile that fits a low-growth, high-cash BCG Cash Cow.
On-X prosthetic aortic valve; established mechanical valve; FDA-approved
On-X, FDA-approved since 2001, has built a 24-year installed base in valve surgery, which supports repeat follow-up and replacement demand for Artivion, Inc. The mechanical valve market is mature and low-growth, so pricing stays disciplined and margins tend to hold up. That makes On-X a steady cash cow, not a growth driver.
On-X prosthetic mitral valve; mature valve franchise; repeat clinical demand
On-X prosthetic mitral valve sits in a mature surgical niche: mitral valve replacement is an established, low-growth category, so share matters more than category expansion. Surgeon familiarity and long implant life cycles support repeat clinical demand, while the premium mechanical-valve mix helps Artivion convert steady volume into cash. In a slow-growth market, even small share gains can throw off reliable operating cash.
CryoVein and CryoArtery; preserved human tissues; recurring hospital use
CryoVein and CryoArtery sit in Artivion, Inc.’s cash-cow zone: these preserved human tissues support steady vascular surgery demand and are used repeatedly in hospital workflows. Their maturity means slower growth but reliable sales, with recurring supply ties that help keep margins and cash flow stable.
- Recurring hospital use supports repeat orders.
- Mature tissue products usually bring steady revenue.
- Cash generation helps fund growth businesses.
Pyrolytic carbon coating services; OEM service line; specialized manufacturing
Artivion, Inc.’s pyrolytic carbon coating services are a niche OEM line for other medical device makers, so they fit a Cash Cow: steady demand, high specialization, and limited need for rapid market expansion. In FY2025, Artivion kept this kind of legacy manufacturing anchored inside a business that still serves 100+ countries, which supports repeat orders and cash flow over growth chasing.
- Specialized, not growth-led
- OEM demand is repeatable
- Cash flow matters more than scale
Artivion’s Cash Cows Power Steady Global Growth
Artivion, Inc.’s Cash Cows are BioGlue, On-X, CryoVein, CryoArtery, and pyrolytic carbon coating services. In FY2025, these mature lines supported repeat hospital and OEM demand, with Artivion selling in 100+ countries and leaning on long product life cycles for steady cash. On-X has a 24-year installed base, and BioGlue still spans four surgery areas.
| Cash Cow | Why it fits | Key fact |
|---|---|---|
| BioGlue | Repeat use | 4 surgery areas |
| On-X | Mature valve | FDA-approved 2001 |
| CryoVein | Steady tissue demand | Recurring hospital use |
Preview Before You Purchase
Artivion, Inc. Reference Sources
The Artivion, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the full, polished report ready for immediate use. Once purchased, the file is delivered in the same format for easy reviewing, sharing, or presentation. What you preview is what you get.
Dogs
Cardiac laser therapy for angina; legacy therapy; limited adoption
Cardiac laser therapy for angina is a legacy niche, and modern PCI and CABG have taken most of the demand. With U.S. PCI volumes in the hundreds of thousands each year, the category stays weak growth and weak share. For Artivion, Inc., that makes this a clear Dogs business: limited adoption, low strategic pull, and little pricing power.
PerClot absorbable powdered hemostat; crowded market; modest scale
PerClot sits in a crowded hemostatic-powder market dominated by larger surgical brands, so pricing power and shelf space are limited. Its scale is still modest versus Artivion’s aortic franchise, which remains the company’s main growth engine. With small share and limited expansion runway, PerClot fits a classic dog profile in the BCG matrix.
CarbonAid CO2 diffusion catheters; niche accessory; low growth
CarbonAid CO2 diffusion catheters are a narrow-use surgical accessory, not a core platform for Artivion, Inc. Public filings do not break out separate CarbonAid revenue, which usually signals a small, hard-to-scale line. With a limited addressable market and little visible growth, it looks more like a cash trap than a growth engine.
Chord-X ePTFE sutures; mitral chordal replacement; narrow niche
Chord-X ePTFE sutures for mitral chordal replacement fit a narrow surgical niche, not a scale market. Mitral valve repair is specialized, and Artivion’s broader 2025 revenue base was about $0.4B, so this line is too small to move group growth. Low share, limited procedure volume, and modest expansion potential point to Dog status.
- Very specific surgical use case
- Small addressable market
- Low share, weak growth upside
- BCG Dog fit
Synthetic vascular grafts; commoditized open surgery line; price pressure
Artivion, Inc.'s synthetic vascular grafts sit in a mature open-surgery market where rivals compete mostly on price, not differentiation. That makes growth modest and returns weak; the line is usually a lower-priority capital allocation choice versus higher-growth aortic and adjunct platforms. Open grafts are classic Dogs when pricing pressure compresses margins.
- Mature category
- High price pressure
- Limited differentiation
- Low strategic priority
Artivion’s Dogs: Small, Crowded, and Low-Growth
Artivion, Inc.’s Dogs are small, low-growth lines with weak share and little pricing power. Cardiac laser therapy, PerClot, CarbonAid, Chord-X, and synthetic grafts all sit in narrow or mature niches, while Artivion, Inc.’s 2025 revenue was about $0.4B, led by the aortic franchise.
| Item | Signal |
|---|---|
| PerClot | Crowded hemostatic niche |
| CarbonAid | Small, non-core accessory |
| Synthetic grafts | Mature, price-led market |
Question Marks
E-xtra design engineering systems; custom aortic devices; high-complexity segment
Artivion, Inc.'s E-xtra design engineering systems for custom aortic devices fit the Question Mark box: demand is rising because complex aortic anatomy often needs patient-specific repair, but the niche is still small and crowded. These devices usually sell through high-volume specialist centers, so growth depends on clinical proof, surgeon training, and long sales cycles. That makes share possible to build, but it needs heavy commercial support and keeps capital intensity high.
E-nya; minimally invasive descending aorta repair; expansion product
E-nya sits in a growing aortic disease market, where endovascular repair keeps taking share from open surgery. Still, Artivion is building broad penetration, so the product has upside but not yet the scale of a market leader. In BCG terms, that mix of rising demand and limited share makes E-nya a question mark, not a cash cow.
E-ventus BX; balloon-expandable stent graft; peripheral and renal use
E-ventus BX sits in a question mark: peripheral and renal aortic-adjacent therapies are attractive growth pools, but Artivion has not yet turned clinical interest into clear share leadership. The bet is on conversion, not scale today, so sales, evidence, and surgeon adoption need more investment. In Artivion's 2025 base, this type of niche therapy still looks like a small but optionality-rich growth driver.
E-liac; iliac aneurysm system; branch treatment niche
E-liac sits in a niche branch-treatment market: iliac aneurysms make up about 10% to 20% of abdominal aortic aneurysms, so the pool is specialized but real. Adoption still depends on physician familiarity and payer approval, and that keeps share in a build phase rather than a mature one.
- Specialized, not mass-market.
- Growth tied to reimbursement.
- Physician training drives adoption.
- Share is still developing.
E-vita Open Plus; older-generation aortic platform; transition stage
E-vita Open Plus is an older aortic platform, so it can still sell, but newer systems usually take share in a growing market. Artivion, Inc. has not broken out platform-level 2025/2026 sales, so its exact momentum is harder to track. That mix of continued use and weaker relative growth fits the question-mark zone.
- Legacy product, still relevant
- Share pressure from newer versions
- Growth needs more investment
- Unclear if returns will scale
Artivion’s Niche Bets Aim at Growing Aortic Demand
Artivion, Inc.'s question marks are niche growth bets: E-xtra, E-nya, E-ventus BX, and E-liac all target rising aortic demand, but share is still building. E-liac serves a 10% to 20% AAA segment, so the pool is real but specialized. E-vita Open Plus stays relevant, yet newer platforms are taking share, so all need more sales, evidence, and training.
| Product | Status |
|---|---|
| E-liac | 10% to 20% AAA niche |
| E-vita Open Plus | Legacy share under pressure |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.